Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | PYGL | P06737 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.49 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ESRRA | P11474 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791892 | 0.89 | ALDH1A1 (0.60) | PYGLRORCALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL14341158 | 0.81 | PYGL (0.50) | PYGLRORCALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL9472463 | 0.81 | PYGL (0.50) | PYGLRORCALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4548035 | 0.81 | EPHX1 (0.70) | HTTRORCKMT2ASMN1; SMN2POLB | |
| SCHEMBL7936658 | 0.79 | KMT2A (0.54) | PYGLRORCALDH1A1KMT2APOLB | |
| SCHEMBL9231822 | 0.79 | HTT (0.54) | HTTPYGLALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3786506 | 0.78 | ALDH1A1 (0.37) | PYGLALDH1A1KMT2AEPHX1EPHX2 | |
| SCHEMBL405569 | 0.78 | SMN1; SMN2 (0.59) | HTTRORCALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3786387 | 0.78 | CA1 (0.58) | RORCALDH1A1KMT2ASMN1; SMN2ESRRA | |
| SCHEMBL13602308 | 0.78 | SMN1; SMN2 (0.59) | HTTPYGLRORCALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20080165668-A1 | RECORDING MEDIUM AND INFORMATION RECORDING AND REPRODUCING METHOD USING THE SAME | FUJIFILM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080165668-A1 | RECORDING MEDIUM AND INFORMATION RECORDING AND REPRODUCING METHOD USING THE SAME | FUJIFILM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | HTT 3655/4885PYGL 4326/4885RORC 1079/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | HTT 4769/4885PYGL 2362/4885RORC 2565/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | HTT 3668/4885PYGL 2351/4885RORC 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.